Expertise in
7
conditions

Dr. Philip D. Leming

Hematology
The Christ Hospital
2139 Auburn Ave, 
Cincinnati, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
The Christ Hospital
2139 Auburn Ave, 
Cincinnati, OH 

Overview

Philip Leming is a Hematologist practicing medicine in Cincinnati, Ohio.

Dr. Leming is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Small Lymphocytic Lymphoma (SLL), Febrile Neutropenia, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Endoscopy.

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

The Christ Hospital
2139 Auburn Ave, Cincinnati, OH 45219

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Drug
Study Drug: Carvedilol
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Biological
Study Drugs: Bevacizumab, Ipilimumab
Study Phase: Phase 2
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drugs: Cirmtuzumab, Ibrutinib
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Biological
Study Phase: Phase 1
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
Enrollment Status: Terminated
Publish Date: September 03, 2020
Intervention Type: Biological, Other
Study Phase: Phase 1
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
View 7 Less Clinical Trials

13 Total Publications

A New Approach to Cancer Second Opinions: Overcoming the Challenges of Conventional Oncology Practice by Providing Education to Patients and Physicians.
A New Approach to Cancer Second Opinions: Overcoming the Challenges of Conventional Oncology Practice by Providing Education to Patients and Physicians.
Journal: Journal of cancer education : the official journal of the American Association for Cancer Education
Published: March 08, 2025
Similar Doctors
Expertise in
21
conditions
Dr. John C. Byrd
Hematology
Expertise in
21
conditions
Dr. John C. Byrd
Hematology
Referral may be required

Hoxworth Center

3130 Highland Ave, 
Cincinnati, OH 
 (1.1 miles away)
513-584-4268
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Byrd is a Hematologist practicing medicine in Cincinnati, Ohio. Dr. Byrd is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Byrd is currently accepting new patients.

Expertise in
22
conditions
Dr. Kasiani C. Myers
Hematology | Oncology
Expertise in
22
conditions
Dr. Kasiani C. Myers
Hematology | Oncology
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (1.4 miles away)
513-636-4266
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

Kasiani Myers is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Myers is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Shwachman-Diamond Syndrome, Congenital Aplastic Anemia, Fanconi Anemia, Aplastic Anemia, and Bone Marrow Transplant. Dr. Myers is currently accepting new patients.

Expertise in
13
conditions
Dr. Russell E. Ware
Hematology | Oncology
Expertise in
13
conditions
Dr. Russell E. Ware
Hematology | Oncology
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (1.4 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Russell Ware is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Ware is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Splenectomy. Dr. Ware is currently accepting new patients.

Frequently Asked Questions about Dr. Philip D. Leming

How do I make an appointment with Dr. Philip D. Leming?

You can book an appointment with Dr. Philip D. Leming by calling their office at 513-585-1210. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Philip D. Leming a top-rated expert for Small Lymphocytic Lymphoma (SLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Philip D. Leming is classified as an Distinguished expert for Small Lymphocytic Lymphoma (SLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Philip D. Leming specialize in?

While Dr. Philip D. Leming is a Hematology, they have specific expertise in Small Lymphocytic Lymphoma (SLL), Febrile Neutropenia, and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Philip D. Leming participate in research or clinical trials?

Yes. Dr. Philip D. Leming has published 13 articles and abstracts on conditions like Small Lymphocytic Lymphoma (SLL). You can view a list of Dr. Philip D. Leming's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Leming's expertise for a condition
ConditionClose
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile